Refine your search
Content Type
Publication Name
Author
- Tony Pistilli (5)
- Greg Warren (4)
- Traci Leigh Hughes (2)
- Keith Passwater (2)
- James Dolstad (2)
- Sudha Shenoy (1)
- Stoddard Davenport (1)
- Sam Johnmeyer (1)
- Rowen Bell (1)
- Robert T Eaton (1)
- Robert Lang (1)
- Peter Robinson (1)
- Maria Knox (1)
- Lisa Swan (1)
- Kristi Bohn (1)
- Kirsten Staveland (1)
- Kenneth J Clark (1)
- Justin Hartmann (1)
- Julia Friedman (1)
- Joan Barrett (1)
- Jill Van Den Bos (1)
- Jennifer Howard (1)
- James Pisko (1)
- Ian G Duncan (1)
- Gregory Warren (1)
- Gregory L Warren (1)
- Greg Fann (1)
- Gail Stone (1)
- Elliot McLeRoy (1)
- Derek Ray (1)
- David Nelson (1)
- Daniel Reck (Dan) (1)
- Craig Cartossa (1)
- Charles Edwards (1)
- Brian Parkinson (1)
- Ashlee Borcan (1)
- Andrew Mackenzie (1)
- Abby Steele (1)
- Show More Show Less
Site
Topic
- Health & Disability (19)
- Health insurance (14)
- Health care (13)
- Health care quality (7)
- Health risks (5)
- Public Policy, Law & Regulation (4)
- Provider risk (4)
- Health policy (3)
- Predictive Analytics (3)
- Health care reform (2)
- Modeling techniques (2)
- Rates - Health & Disability (2)
- Provider networks (2)
- Payment models (2)
- Chronic health management - Health & Disability (2)
- Financial Reporting & Accounting (2)
- Morbidity (2)
- Experience Studies & Data (2)
- Technology & Applications (1)
- Medicare (1)
- Reinsurance (1)
- Termination - Long-term Care (1)
- Rates - Long-term Care (1)
- Long-term care pricing (1)
- Termination - Health & Disability (1)
- Incidence (1)
- Claims - Health & Disability (1)
- Public financing - Health & Disability (1)
- Critical illness insurance (1)
- Global Perspectives (1)
- Statutory accounting (1)
- Generally Accepted Accounting Principles [GAAP] (1)
- Rate calculations (1)
- Risk measurement - ERM (1)
- Risk appetite (1)
- Actuarial Profession (1)
- Show More Show Less
31
-
31
of
31
results (0.34 seconds)
Sort By:
-
Biosimilars, Part 1: A Brief Introduction
Biosimilars, Part 1: A Brief Introduction What are Biosimilar drugs? Are they the same as generic drugs? What potential impact might Biosimilars have in the United States prescription drug ...Description: What are Biosimilar drugs? Are they the same as generic drugs? What potential impact might Biosimilars have in the United States prescription drug landscape and it’s economics? This article explores those questions as well as exclusivity and interchangeability.
Hide- Authors: Gregory Warren, Tony Pistilli
- Date: Sep 2023
- Competency: External Forces & Industry Knowledge
- Publication Name: Health Watch
- Topics: Health & Disability